If the merger of Pfizer’s off-patent drug unit and Mylan is approved, Mylan CEO Heather Bresch could earn more than $37.6 million in severance and vested benefits, according to The Pittsburgh Post ...

Pfizer will merge its off-patent drug business with generic drugmaker Mylan, a move that would create a lower-priced medication powerhouse, according to The Wall Street Journal. The combined company ...

Viatris Inc. investors can’t proceed with a lawsuit claiming the drugmaker misrepresented its commitment to its biosimilars business segment, the Third Circuit said Thursday.

NEW YORK -- The FDA issued a warning to patients about the EpiPen on Tuesday. In a news release, FDA said EpiPen manufacturers Pfizer and Mylan sent a letter to health care providers noting the EpiPen ...

Viatris on Thursday beat Wall Street estimates for third-quarter results, driven by strong demand for its branded drugs in China and emerging markets, and raised its forecasts for 2025 profit and ...

PITTSBURGH — Mylan has launched a generic drug for fungal infections, the company said Tuesday. Mylan announced the launch, through subsidiary Mylan Pharmaceuticals, of voriconazole tablets in the ...

The U.S. Food and Drug Administration sent a warning letter to Meridian Medical Technologies, a unit of Pfizer, charging that it failed to investigate multiple complaints that some EpiPen ...

NEW YORK--(BUSINESS WIRE)--Nussbaum Law Group, P.C. and Roberts Law Firm US, PC: A proposed settlement (“Settlement”) has been reached in a class action lawsuit alleging that Mylan N.V., Mylan ...

Beginning in 2020, Upjohn began managing Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan ...

PITTSBURGH — Mylan has launched the first generic version of a drug used to treat fungal infections, the company said Monday. The drug maker announced the launch of voriconazole for oral suspension in ...